Fenquizone
Chemical compound
- C03BA13 (WHO)
- 7-chloro-4-oxo-2-phenyl-1,2,3,4-tetrahydroquinazoline-6-sulfonamide
- 20287-37-0
- 68548
- 61822 Y
- LJ1U13R8IK
- D04161 Y
- DTXSID10864933
- Interactive image
- O=S(=O)(c3c(Cl)cc2c(C(=O)NC(c1ccccc1)N2)c3)N
InChI
- InChI=1S/C14H12ClN3O3S/c15-10-7-11-9(6-12(10)22(16,20)21)14(19)18-13(17-11)8-4-2-1-3-5-8/h1-7,13,17H,(H,18,19)(H2,16,20,21) Y
- Key:DBDTUXMDTSTPQZ-UHFFFAOYSA-N Y
Fenquizone (INN) is a diuretic, part of the class of low-ceiling sulfonamide diuretics.[1] Fenquizone is used primarily in the treatment of oedema and hypertension.[2]
See also
- Quinethazone
- Metolazone
References
- ^ Ferrando C, Foy JM, Pratt CN, Purvis JR (April 1981). "On the pharmacological actions of a diuretic, fenquizone, with particular reference to its site of action". The Journal of Pharmacy and Pharmacology. 33 (4): 219–22. doi:10.1111/j.2042-7158.1981.tb13761.x. PMID 6115903.
- ^ "Fenquizone". Drug Information from MIMS. Thailand.[permanent dead link]
- v
- t
- e
Diuretics (C03)
(and etacrynic acid)
CA inhibitors (at PT) | |
---|---|
Loop (Na-K-Cl at AL) | |
Thiazides (Na-Cl at DCT, Calcium-sparing) | |
Thiazide-likes (primarily DCT) |
ESC blockers | |
---|---|
Aldosterone antagonists |
(DCT and CD)
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e